Brokerage firm Cowen & Co. Downgrades its rating on Raptor Pharmaceutical Corp.(NASDAQ:RPTP). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by Cowen & Co. was issued on Sep 16, 2016.
In a different note, On Aug 9, 2016, Citigroup said it Maintains its rating on Raptor Pharmaceutical Corp.. In the research note, the firm Raises the price-target to $6.00 per share. The shares have been rated ‘Neutral’ by the firm. On Aug 8, 2016, Citigroup said it Downgrades its rating on Raptor Pharmaceutical Corp.. In the research note, the firm Raises the price-target to $6.00 per share. The shares have been rated ‘Neutral’ by the firm.
Raptor Pharmaceutical Corp. (RPTP) shares turned negative on Thursdays trading session with the shares closing down -0.025 points or -0.28% at a volume of 12,21,624. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $9.01. The peak price level was also seen at $9.01 while the days lowest was $8.96. Finally the shares closed at $8.965. The 52-week high of the shares is $8.99 while the 52-week low is $2.94. According to the latest information available, the market cap of the company is $765 M.
Raptor Pharmaceutical Corp.(RPTP) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $32.05M. Analysts had an estimated revenue of $28.52M. Earnings per share were $-0.16. Analysts had estimated an EPS of $-0.18.
Several Insider Transactions has been reported to the SEC. On Sep 11, 2015, Suzanne Louise Bruhn (director) sold 18,258 shares at $12.47 per share price.Also, On Sep 4, 2015, Raymond Anderson (director) sold 4,916 shares at $12.51 per share price.On Jul 2, 2015, Llew Keltner (director) sold 50,000 shares at $16.05 per share price, according to the Form-4 filing with the securities and exchange commission.
Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company’s product PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe PROCYSBI gastro-resistant hard capsules of cysteamine received a marketing authorization from the European Commission (EC) as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Company’s pipeline includes its delayed-release form of cysteamine or RP103 and its oral 4-methylpyrazole or Convivia. Its other product Quinsair is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.